Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...
Shares of Bright Minds Biosciences on Friday shot higher after pricing a $35 million private placement. The stock was up 70% at $36.86 in pre-market trading. The company said it has priced the private ...
On Friday, Bright Minds Biosciences Inc (DRUG) stock saw a modest uptick, ending the day at $47.21 which represents a slight increase of $25.51 or 117.56% from the prior close of $21.7. The stock ...
After two days of declines, shares of Bright Minds Biosciences (NASDAQ:DRUG) bounced back in the premarket on Friday with a ~48% rise after the psychedelic drug developer announced a private ...
18, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered private placement of common ...